GlassScriptPhysician profile
Alex Saulkumar Honest
NPI 1700512563
$1,414.06
in general payments reported to CMS, 2019-2025
20 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.09 · 2023: $13.62 · 2024: $36.32 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $202.24 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $190.50 | 2025 | Caplyta |
| Dexcom, INC. | $130.81 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amgen INC. | $120.57 | 2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $119.64 | 2025 | Airsupra, Farxiga |
| Boston Scientific Corporation | $114.57 | 2025 | Accolade Sr |
| Abbvie INC. | $96.14 | 2025 | |
| Noven Therapeutics, LLC | $56.99 | 2025 | Xelstrym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.54 | 2025 | Jardiance |
| Corium, LLC | $45.55 | 2025 | Azstarys |
| Pfizer INC. | $45.04 | 2025 | |
| Antares Pharma, INC. | $41.34 | 2025 | Xyosted |
| Viatris Specialty LLC | $38.98 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $31.27 | 2025 | |
| Organon LLC | $28.71 | 2022-2023 | Nexplanon |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.25 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $21.26 | 2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $19.15 | 2024 | |
| Phathom Pharmaceuticals, INC. | $17.34 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $17.17 | 2024 | Gardasil, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Honest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.